Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Year of publication
Document Type
- Journal article (20)
Language
- English (20)
Keywords
- HIV (4)
- antiretroviral therapy (3)
- German Hepatitis C-Registry (2)
- chronic hepatitis C (2)
- graft versus host disease (2)
- hepatitis C virus (2)
- infection (2)
- sofosbuvir (2)
- therapeutic drug monitoring (2)
- AIDS (1)
- APRI (1)
- ARDS (acute respiratory distress syndrome) (1)
- BRAF mutation (1)
- COVID-19 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- D insufficiency (1)
- D serum-levels (1)
- FIB-4 (1)
- Germany (1)
- HBV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HIV diagnosis and management (1)
- HIV infections (1)
- HIV-1-infected patients (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- IL28B polymorphisms (1)
- LINE-1 retrotransposition (1)
- Prednisolon (1)
- Ruxolitinib (1)
- T cells (1)
- Tansania (1)
- Tanzania (1)
- Uganda (1)
- acoustic radiation force impulse imaging (1)
- active antiretroviral therapy (1)
- adults (1)
- afatinib (1)
- all-cause mortality (1)
- antimicrobial resistance (1)
- antiretrovirals (1)
- at-home sampling (1)
- bile (1)
- biomarkers (1)
- chemokines (1)
- chronic Hepatitis C (1)
- cirrhosis (1)
- coagulation (1)
- common genetic determinants (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- differentiated thyroid tumor (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- disease (1)
- drug adherence (1)
- drug interactions (1)
- drug monitoring (1)
- drug–drug interactions (DDIs) (1)
- elderly persons (1)
- epidemology (1)
- fibrin D-dimer (1)
- fibrotest (1)
- glecaprevir/pibrentasvir (1)
- healthy volunteers (1)
- highly-active antiretroviral therapy (1)
- human hepatic cells (1)
- hydroxy-dabrafenib (1)
- i-131 uptake (1)
- immune activation (1)
- immune cells (1)
- indinavir (1)
- intensive care medicine (1)
- interferon alpha (1)
- interferon-free (1)
- interleukin-6 (1)
- kinase inhibitors (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liver (1)
- liver diseases (1)
- management (1)
- melanoma (1)
- mutation databases (1)
- non-invasive fibrosis assessment (1)
- osimertinib (1)
- pandemia (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- point shear wave elastography (1)
- population pharmacokinetics (1)
- posaconazole (1)
- prostate cancer (1)
- randomized controlled-trial (1)
- real world evidence (1)
- reverse-transcriptase inhibitors (1)
- routine clinical-practice (1)
- ruxolitinib (1)
- sequence databases (1)
- severe fibrosis (1)
- steatosis (1)
- sustained virological response (1)
- therapy (1)
- toxicity (1)
- trametinib (1)
- transient elastography (1)
- viral clearance (1)
- viral load (1)
- viral replication (1)
- virus infection (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- weight gain (1)
Institute
- Medizinische Klinik und Poliklinik II (15)
- Institut für Virologie und Immunbiologie (5)
- Medizinische Klinik und Poliklinik I (5)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Mathematik (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Missionsärztliche Klinik (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 241447 (1)
Background: The World Health Organization (WHO) has recommended guidelines for a HIV drug resistance (HIVDR) survey for resource-limited countries. Eligibility criteria for patients include age below 25 years in order to focus on the prevalence of transmitted HIVDR (tHIVDR) in newly-infected individuals. Most of the participating sites across Africa have so far reported tHIVDR prevalences of below 5%. In this study we investigated whether the rate of HIVDR in patients ,25 years is representative for HIVDR in the rest of the therapy-naive population. Methods and Findings: HIVDR was determined in 88 sequentially enrolled ART-naive patients from Mwanza, Tanzania (mean age 35.4 years). Twenty patients were aged, 25 years and 68 patients were aged 25–63 years. The frequency of HIVDR in the study population was 14.8% (95%; CI 0.072–0.223) and independent of NVP-resistance induced by prevention of mother-to-child transmission programs. Patients .25 years had a significantly higher HIVDR frequency than younger patients (19.1%; 95% CI 0.095–0.28) versus 0%, P = 0.0344). In 2 out of the 16 patients with HIVDR we found traces of antiretrovirals (ARVs) in plasma. Conclusions: ART-naive patients aged over 25 years exhibited significantly higher HIVDR than younger patients. Detection of traces of ARVs in individuals with HIVDR suggests that besides transmission, undisclosed misuse of ARVs may constitute a significant factor in the generation of the observed high HIVDR rate. The current WHO tHIVDR survey that is solely focused on the transmission of HIVDR and that excludes patients over 25 years of age may therefore result in substantial underestimation of the prevalence of HIVDR in the therapy-naive population. Similar studies should be performed also in other areas to test whether the so far reported optimistic picture of low HIVDR prevalence in young individuals is really representative for the rest of the ART-naive HIV-infected population.